Taku Wakabayashi

Aug 26, 2024 | nature.com | Ashish Sharma |Peter Kaiser |Frank G. Holz |Sobha Sivaprasad |Taku Wakabayashi |Nilesh Kumar | +3 more

The majority (95.2%) of the ophthalmologists were aware of all the ranibizumab biosimilars available in India. Biosimilar ranibizumab was the most common ranibizumab administered with 50–100% usage in 51% respondents whereas the proportion of originator usage was below 25% in the majority of practices (62.8%) (Fig. 1B).

Aug 3, 2024 | nature.com | Ashish Sharma |Taku Wakabayashi |Anat Loewenstein |Nilesh Kumar |Francesco Bandello

AbstractTo understand subfoveal neurosensory detachment flattening and observe (SNF-Ob) strategy and its relationship with visual acuity in the management of centre-involved diabetic macular oedema (Ci-DMO). This was a multicentric retrospective observational study. We reviewed data of 188 eyes of 130 patients who presented with Ci-DMO with subfoveal neurosensory detachment (NSD) and treated with intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents or steroids.

Jul 23, 2024 | nature.com | Taku Wakabayashi |Ashish Sharma

Anti-vascular endothelial growth factor (VEGF) injections are the mainstay of treatment for retinal vascular diseases. However, despite their efficacy, the cost of long term intravitreal injections poses a significant burden on patients and healthcare systems. Recently, ranibizumab biosimilar (ranibizumab BS1, Senju Pharmaceuticals Co Ltd) has become available in Japan [1].